Key result
Stepwise approach successfully retrieves and reimplants an immediately dislodged AVEIR VR leadless pacemaker.
Why the study?
The AVEIR helix-fixation leadless pacemaker system has proven safety and efficacy, but cases of device dislodgment and retrieval require detailed reporting to guide implantation.
Case Report (n=1)
This case highlights the risk of premature device migration with helix-fixation leadless pacemakers and details a stepwise approach for retrieval and reimplantation.
The AVEIRTM (Abbott, Chicago, IL) helix-fixation leadless pacemaker (LP) system received Food and Drug Administration approval in April 2022. The device has proven safety and efficacy in the LEADLESS II clinical trial.1 We present a 93-year-old man who was admitted to the hospital with symptomatic sinus bradycardia. After shared decision-making, the patient underwent AVEIR VR leadless pacemaker placement. Immediately after implantation, the device had dislodged. We detail a stepwise approach for retrieval and reimplantation, highlighting potential reasons for premature device migration and key points for successful implantation.
No takes yet. Share an insight, caveat, or question.
Haddadin et al. (2024) conducted a case report in Symptomatic sinus bradycardia (n=1). AVEIR VR leadless pacemaker placement was evaluated. AVEIR VR leadless pacemaker dislodged immediately after implantation in a 93-year-old man, requiring a stepwise approach for retrieval and reimplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: